BR112017018230A2 - forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina - Google Patents
forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalinaInfo
- Publication number
- BR112017018230A2 BR112017018230A2 BR112017018230A BR112017018230A BR112017018230A2 BR 112017018230 A2 BR112017018230 A2 BR 112017018230A2 BR 112017018230 A BR112017018230 A BR 112017018230A BR 112017018230 A BR112017018230 A BR 112017018230A BR 112017018230 A2 BR112017018230 A2 BR 112017018230A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- disorder
- disease
- treating
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- BAZRWWGASYWYGB-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1[C@H](N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1CC1)=CN2 BAZRWWGASYWYGB-SNVBAGLBSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121396P | 2015-02-26 | 2015-02-26 | |
| PCT/US2016/019904 WO2016138458A1 (en) | 2015-02-26 | 2016-02-26 | Crystalline forms of a pyrrolopyridine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017018230A2 true BR112017018230A2 (pt) | 2018-04-17 |
Family
ID=55521844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017018230A BR112017018230A2 (pt) | 2015-02-26 | 2016-02-26 | forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20160251350A1 (https=) |
| EP (1) | EP3262042A1 (https=) |
| JP (1) | JP2018506562A (https=) |
| KR (1) | KR20170118762A (https=) |
| CN (1) | CN107406447A (https=) |
| AR (1) | AR103801A1 (https=) |
| AU (1) | AU2016225070A1 (https=) |
| BR (1) | BR112017018230A2 (https=) |
| CA (1) | CA2976665A1 (https=) |
| CL (1) | CL2017002180A1 (https=) |
| CO (1) | CO2017009662A2 (https=) |
| CR (1) | CR20170439A (https=) |
| HK (1) | HK1246786A1 (https=) |
| IL (1) | IL254115A0 (https=) |
| MA (1) | MA41599A (https=) |
| MX (1) | MX2017010888A (https=) |
| PE (1) | PE20171327A1 (https=) |
| PH (1) | PH12017501532A1 (https=) |
| RU (1) | RU2017133093A (https=) |
| SG (1) | SG11201706824TA (https=) |
| WO (1) | WO2016138458A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115385871A (zh) * | 2019-01-29 | 2022-11-25 | 沪亚生物国际有限公司 | 舒欣啶盐 |
| EP3923948A4 (en) * | 2019-02-12 | 2022-11-16 | Impact Biomedicines, Inc. | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| KR102325163B1 (ko) * | 2013-08-22 | 2021-11-11 | 제넨테크, 인크. | 화합물의 제조 방법 |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
-
2016
- 2016-02-25 MA MA041599A patent/MA41599A/fr unknown
- 2016-02-26 RU RU2017133093A patent/RU2017133093A/ru not_active Application Discontinuation
- 2016-02-26 AR ARP160100511A patent/AR103801A1/es unknown
- 2016-02-26 AU AU2016225070A patent/AU2016225070A1/en not_active Abandoned
- 2016-02-26 HK HK18106266.4A patent/HK1246786A1/zh unknown
- 2016-02-26 SG SG11201706824TA patent/SG11201706824TA/en unknown
- 2016-02-26 CR CR20170439A patent/CR20170439A/es unknown
- 2016-02-26 PE PE2017001459A patent/PE20171327A1/es unknown
- 2016-02-26 KR KR1020177023996A patent/KR20170118762A/ko not_active Withdrawn
- 2016-02-26 EP EP16709228.7A patent/EP3262042A1/en not_active Withdrawn
- 2016-02-26 WO PCT/US2016/019904 patent/WO2016138458A1/en not_active Ceased
- 2016-02-26 BR BR112017018230A patent/BR112017018230A2/pt not_active Application Discontinuation
- 2016-02-26 MX MX2017010888A patent/MX2017010888A/es unknown
- 2016-02-26 CN CN201680011960.5A patent/CN107406447A/zh active Pending
- 2016-02-26 US US15/054,611 patent/US20160251350A1/en not_active Abandoned
- 2016-02-26 JP JP2017545269A patent/JP2018506562A/ja not_active Withdrawn
- 2016-02-26 CA CA2976665A patent/CA2976665A1/en not_active Abandoned
-
2017
- 2017-08-23 IL IL254115A patent/IL254115A0/en unknown
- 2017-08-24 PH PH12017501532A patent/PH12017501532A1/en unknown
- 2017-08-25 CL CL2017002180A patent/CL2017002180A1/es unknown
- 2017-09-25 CO CONC2017/0009662A patent/CO2017009662A2/es unknown
- 2017-11-08 US US15/806,650 patent/US20180282324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017002180A1 (es) | 2018-03-16 |
| KR20170118762A (ko) | 2017-10-25 |
| HK1246786A1 (zh) | 2018-09-14 |
| PE20171327A1 (es) | 2017-09-12 |
| WO2016138458A1 (en) | 2016-09-01 |
| IL254115A0 (en) | 2017-10-31 |
| AR103801A1 (es) | 2017-06-07 |
| SG11201706824TA (en) | 2017-09-28 |
| PH12017501532A1 (en) | 2018-02-05 |
| MA41599A (fr) | 2018-01-02 |
| AU2016225070A1 (en) | 2017-09-07 |
| US20160251350A1 (en) | 2016-09-01 |
| US20180282324A1 (en) | 2018-10-04 |
| JP2018506562A (ja) | 2018-03-08 |
| EP3262042A1 (en) | 2018-01-03 |
| CR20170439A (es) | 2018-01-08 |
| MX2017010888A (es) | 2017-12-15 |
| RU2017133093A (ru) | 2019-03-26 |
| CN107406447A (zh) | 2017-11-28 |
| CO2017009662A2 (es) | 2018-02-28 |
| RU2017133093A3 (https=) | 2019-08-23 |
| CA2976665A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| PL3601268T3 (pl) | Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
| EA201890123A1 (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| PH12018501362A1 (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| DK3385262T3 (da) | 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| BR112016021130A2 (pt) | Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas | |
| NI201800112A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6- (trifluorometil)piridin-2-carboxamida | |
| BR112017026132A2 (pt) | piridinas substituídas e métodos de uso | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MX393177B (es) | Formulacion granulada de 5-metil-1-fenil-2-(1h)-piridona y metodo para elaborarla. | |
| MX376164B (es) | Composiciones y metodos para tratar el insomnio. | |
| PH12017501699A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| BR112019003320A2 (pt) | compostos de heteroaril carboxamida como inibidores de ripk2 | |
| MX2021015656A (es) | Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| DK3634968T3 (da) | Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf | |
| CY1125399T1 (el) | Διαρυλικες συνθεσεις και μεθοδοι για τη διαμορφωση ενος καταρρακτη κινασης | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| BR112017018230A2 (pt) | forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina | |
| DK3398946T3 (da) | Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme | |
| MX2020009412A (es) | Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |